Search

A Canadian consortium, which includes Lawson Health Research Institute (Lawson), TRIUMF, BC Cancer and Centre for Probe Development and Commercialization, is the first in the world to receive regulatory approval to produce the world’s most commonly used medical isotope, technetium-99m (Tc-99m), using small particle accelerators known as cyclotrons. 

Tc-99m is used in tens of millions of nuclear medicine procedures globally each year. These include cancer scans, cardiac tests, as well as several other diagnostic procedures. As the world moves away from uranium-based nuclear reactors, there has been growing concern in the medical community of a global shortage of these life-saving compounds. This development helps secure a domestic supply of Tc-99m for Canadian patients.

For over a decade, Dr. Michael Kovacs, Director, Lawson Cyclotron & PET Radiochemistry Facility, and Steven Foster, Business Manager, Lawson Imaging, have been working on research that has contributed significantly to this major development. They have demonstrated the successful production of Tc-99m on a standard hospital-based cyclotron at Lawson, confirming that this technology can be used by almost half of the world’s already installed cyclotrons. Clinical trials were conducted across Canada and locally at St. Joseph’s Health Care London.

“In 2011, we received federal funding to see if we could develop a technology to produce Tc-99m in hospital cyclotrons,” explains Dr. Kovacs. “Canada’s Chalk River nuclear reactor was one of the world’s largest suppliers, and it was set to close in 2016. Cyclotron facilities offer a greener, safer, more sustainable approach for producing critical medical isotopes. Our goal was to find an alternative to the traditional means of producing this isotope, and we have been successful.”

Nuclear medicine is a functional imaging technique, meaning that it images biological function. Medical isotopes are converted to radiopharmaceuticals which get injected into the patient during a procedure. According to the specific biological properties of the isotope, they move throughout the body, rendering a 3D map of where the isotope has gone. This gives researchers and medical professionals valuable information of how various physiological processes are performing.

“Canada is a global leader in nuclear imaging technology. With the help of our collaborators across the country, we have home-grown technology to produce commercial quantities of Tc-99m on common cyclotrons,” adds Mr. Foster.  “This technology has been patented and licensed to ARTMS Inc., a spin-off from the consortium, and is now being commercialized and sold throughout the world.”

The process was approved by Health Canada in November, 2020, and is expected to be deployed in British Columbia by 2022. 

Two new interventional studies have been brought to London, focused on improving quality of life for patients with Alzheimer’s disease and their caregivers. Both hope to improve upon standard approaches to treating agitation, a core symptom of Alzheimer’s.

Agitation is a significant source of stress for patients and caregivers. It is complex and difficult to treat. Often, families do not know about this particular symptom of Alzheimer’s and are not properly trained on how to manage care while dealing with agitation. 

“These studies are designed to have a direct impact on patients, families and care providers, to improve quality of life and function in those suffering from agitation due to Alzheimer’s,” says Dr. Amer Burhan, Associate Scientist at Lawson Health Research Institute (Lawson) and Geriatric Neuropsychiatrist, St. Joseph’s Health Care London (St. Joseph’s).

Parkwood Institute, a part of St. Joseph’s, is one of multiple sites participating in these studies across Canada and the United States.

One study aims to identify patients early in their diagnosis, while they are living at home or in the community, and apply a comprehensive psychosocial approach, with or without medication, to help with the management of agitation. “We hope to identify participants and have them participating in our program before they experience a crisis due to agitation,” explains Dr. Burhan.

Psychosocial intervention is a way of helping patients and caregivers understand the reasons for agitation. Agitation can develop due to a wide range of causes. For example, patients may just be bored and need help to find something meaningful to occupy their time, they could be upset about something in their current environment, or may be suffering from physical discomfort or pain.

Interventions can include communicating with patients in a manner that creates calm, scheduling meaningful activities, and maintaining routine and rhythm in life. The research team will connect with families early after diagnosis to give them the tools and support they need.

Initially, participants will be treated using structured psychosocial intervention to help reduce and manage their agitation. After three weeks, they will be reassessed and if significant agitation continues to persist, the patient will be randomly selected to receive either a placebo, or medication known as S-Citalopram to treat agitation while they continue to receive psychosocial care.

Sylvia Wilson is the wife of one of the study participants. By enrolling in this trial, she feels she has gained a much better understanding of her husband’s disease, and is grateful for the support that study participants receive.

“My husband typically does not like going to visit doctors, but Dr. Burhan and his team are great,” says Wilson. “They understand agitation, and other symptoms of the disease very well, and I notice a difference in his mood with the treatment he receives through the study.”

Participants are still able to receive care from their primary physician and care teams, with the study providing an added layer of support.

Another study is focused on Alzheimer’s patients who are admitted to hospital or living in long-term care. The aim is to standardize the approach to care for agitation related to Alzheimer’s. After baseline assessment, participants will be randomized to receive the current treatment as per usual, or an integrated care pathway derived from evidence-informed treatment guidelines. These include washing out medications that have not helped, adding individualized behavioral and environmental support, and if medications are needed, use a specific set of medications and dosages based on best evidence. 

“Better understanding agitation is a growing area of interest in geriatric research. The work being done locally is part of an international effort to create a paradigm shift in treating patients with Alzheimer’s disease and agitation,” explains Dr. Burhan.

Researchers are ready to offer these studies to patients and their families, hoping to make these treatment protocols an integral part of care for patients with agitation due to Alzheimer’s disease. Those interested in learning more about these studies can contact Dr. Burhan at @email or call 519-646-6100 x. 48170.

View the trial brochure

In the media: Study on 'agitation' in Alzheimer's patients seeks participants

In recent years deaths from opioid overdoses have become one of the most common injury-related deaths in North America. The continent also has the highest per capita rate of opioid prescription in the world. 

Recognizing the role that opioid prescribing plays in the national opioid crisis, a team of researchers at Lawson Health Research Institute and Western University have developed a new clinical protocol called STOP Narcotics. A study demonstrating the efficacy of their protocol was presented at the American College of Surgeons Clinical Congress in Boston, Massachusetts on October 24. 

The protocol includes a combination of patient and health care provider education and an emphasis on non-opioid pain control. The study found that they were able to reduce the overall amount of opioids being prescribed after general surgery by 50 per cent while still adequately treating a patient’s post-operative pain.   

“By significantly reducing the amount of opioids prescribed, this decreases the exposure risk and potential for misuse of narcotic medication,” said Dr. Luke Hartford, a resident in general surgery at Western’s Schulich School of Medicine & Dentistry and first author on the study. “This also decreases excess medication available to be diverted to individuals for whom it was not intended.”

The study involved 416 patients at London Health Sciences Centre (LHSC) and St. Joseph’s Health Care London who underwent laparoscopic cholecystectomy or open hernia repair. They received medication for post-operative pain through the standardized protocol, specifically acetaminophen (Tylenol) and a non-steroidal anti-inflammatory drug (Naproxen) for the first 72 hours post-surgery. 

The protocol instructs physicians to write a limited prescription of ten pills of opioids (Tramadol), with an expiry date of seven days after surgery, with instructions for the patient to fill this prescription only if adequate pain control was not otherwise achieved. There are also instructions on proper disposal of unused medication for the patient.

Dr. Ken Leslie, scientist at Lawson, associate professor in the Department of Surgery at Schulich Medicine & Dentistry, and Chair/Chief of the Division of General Surgery at London Health Sciences Centre led the implementation of the new protocol.

“We recognized that before STOP Narcotics, every surgeon had a different approach to pain control, and that most surgeons were prescribing more narcotics than are actually needed,” said Dr. Leslie. “When we looked at the data from this new protocol, we saw that the patient’s pain-control was just as good with this pathway, without a huge prescription for narcotics.”

The results showed that in the STOP narcotics group, compared to a control group, there was a 50 per cent reduction in the number of opioids being prescribed. They also demonstrated that only 45 per cent of patients actually filled their opioid prescription, compared to 95 per cent in the control group, and they were also able to increase appropriate disposal of excess opioid medication from 7 per cent in the control group to 23 per cent in the STOP Narcotics group. The levels of reported post-operative pain were the same in both groups.

Image

The group now hopes to expand the protocol for applications beyond general surgery.

“If we can decrease the opioid exposure risk in our patients, and decrease the amount of excess medication available for diversion, and spread this to other institutions and surgical procedures and specialties, this has the potential to significantly impact the opioid crisis,” said Dr. Patrick Murphy, a resident in general surgery at Schulich Medicine & Dentistry and co-author on the study.

The study, “The Standardization of Outpatient Procedure (STOP) Narcotics: A Prospective Noninferiority Study to Reduce Opioid Use in Outpatient General Surgical Procedures,” is published in the Journal of the American College of Surgeons.

Dr. Ken Leslie	Dr. Luke Hartford	Dr. Patrick Murphy
Image	Image	Image

An international team led by scientists from Lawson Health Research Institute and Cedars-Sinai Medical Center are the first to show that Magnetic Resonance Imaging (MRI) can be used to measure how the heart uses oxygen for both healthy patients and those with heart disease. 

Reduced blood flow to the heart muscle is the leading cause of death in the Western world. Currently, the diagnostic tests available to measure blood flow to the heart require injection of radioactive chemicals or contrast agents that change the MRI signal and detect the presence of disease. There are small but finite associated risks and it is not recommended for a variety of patients including those with poor kidney function. 

Standard methods 

More than 500,000 of these tests are performed each year in Canada. A patient suspected of coronary heart disease for example may have reasonably normal blood flow at rest but as soon as they exercise they have pain or feel out of breath. They need more oxygen delivered to the heart tissue but due to vessels being compromised that doesn’t happen. 

The standard technique is usually done in two days with the goal of seeing if the heart can increase blood flow when more oxygen is needed. The first test studies the patient at rest to see what the blood flow is like in the heart. This is a nuclear medicine imaging test that requires radioactive material to be injected and takes about an hour or more to complete.  

They next day, they come for the same test but with the introduction of a stressor. That can be physical exercise but more often they are given an injection of a chemical drug which stimulates the heart and increases blood flow. This is in addition to a second injection of the radioactive material. The heart is imaged to see the level of oxygen getting to different parts of the heart and whether there are obstructions or reduction in size of the surrounding arteries.  

A new stress test

“We wanted a non-invasive way to image the heart and replace the stress stimulus, and drastically reduce the amount of time needed for testing,” says Dr. Frank Prato, Lawson Assistant Director for Imaging. “This new method, cardiac functional MRI (cfMRI), does not require needles or chemicals being injected into the body. It eliminates the existing risks and can be used on all patients."

The team included researchers from Lawson; Cedars-Sinai Medical Center and University of California; King’s College in the United Kingdom; University Health Network and the University of Toronto; Siemens Healthineers; and, University of Edinburgh in the United Kingdom. 

“Our discovery shows that we can use MRI to study heart muscle activity,” explains Dr. Prato. “We’ve been successful in using a pre-clinical model and now we are preparing to show this can be used to accurately detect heart disease in patients.” 

To replace the stress test, this new technique uses repeat exposure to carbon dioxide to test how well the heart’s blood vessels are working to deliver oxygen to the muscle. A breathing machine changes the concentration of carbon dioxide in the blood. Levels are brought up for three minutes and then back down to normal four times. These changes should result in a change in blood flow to the heart, but does not happen when disease is present. 

The cfMRI method reliably detects whether these changes are present and is comparable to the information gathered from the current two-day technique – in much less time and without injections. Dr. Prato notes that “we don’t want to stress the heart. We want to see whether there is capacity in the heart to increase blood flow if the heart needs to work harder.” 

A brilliant discovery 

Other researchers have explored oxygenation-sensitive MRI but initial results contained a high level of ‘noise’ with blurry images. Project leader and partner Dr. Rohan Dharmakumar, Associate Director of the Biomedical Imaging Research Institute at Cedars-Sinai Medical Center, believed that the noise was actually variation in the heart’s processing of oxygen. He engineered a way to average this variation and through testing at Lawson the team discovered that the noise is actually a new way to study how the heart works. 

“We’ve opened the door to a new era and totally novel way of doing cardiac stress testing to identify patients with ischemic heart disease” says Dr. Dharmakumar. “This approach overcomes the limitations of all the current diagnostics – there would no longer be a need for injections or physical stress testing like running on treadmills.” 

Through investigating this technique, they learned that the blurry images were showing normal physiological variability. People often think of heart rate as being stable, but in fact a heart that is unable to keep up with stressors indicates that disease is developing. In a healthy heart, the oxygen distribution to the tissue needs to vary. 

“It’s a very exciting time. We had to bring all the technologies together to be able to image these kinds of changes in blood flow moment to moment,” says Dr. Prato. 
He adds that “using MRI will not only be safer than present methods, but also provide more detailed information and much earlier on in the disease process.” Following initial testing through clinical trials, he sees this being used with patients clinically within a few years.  

Moving forward 

In addition to studying coronary artery disease, the method could be used in other cases where heart blood flow is affected such as the effects of a heart attack or damages to the heart during cancer treatment. Due to its minimal risk, this new tool could be safely used with the same patient multiple times to better select the right treatment and find out early on if it is working. Dr. Prato notes that “with this new window into how the heart works, we have a lot to explore when it comes to the role of oxygen in health and disease.” 

The next steps of the research include a proof of principle study in London, Ontario with 20 patients. Following standard tests using the conventional technique at other sites, the participants will then come in for the experimental test to show that it produces the same result. The research would then move into a multi-centre clinical trial internationally. 

The study “Accurate needle-free assessment of myocardial oxygenation for ischemic heart disease in canines using Magnetic Resonance Imaging” is published in Science Translational Medicine.
 

Researchers in London, Ontario have been awarded $1.345 million over five years through the second phase of the Canadian Consortium on Neurodegeneration in Aging (CCNA), announced today as part of Canada’s first national dementia strategy. CCNA is a collaborative research program tackling the challenge of dementia and other neurodegenerative illnesses. 

A Dementia Strategy for Canada: Together We Aspire focuses on preventing dementia, advancing therapies and finding a cure, as well as improving quality of life for people living with dementia and caregivers. 

Clinician researchers from across the country working together 

Dr. Manuel Montero-Odasso, Scientist at Lawson Health Research Institute, is world renowned for his findings on the relationship between cognition and mobility in the elderly, and gait as a predictor of frailty and dementia. He leads the Mobility, Exercise and Cognition (MEC) Team in London, comprised of top researchers in the areas of mobility, exercise and brain health.

Image

“Evidence from other countries with dementia strategies shows that coordinated, targeted efforts at the national level improves results for all aspects of dementia care and also for research,” says Dr. Montero-Odasso, also a geriatrician and Director of the Gait and Brain Lab at Parkwood Institute, a part of St. Joseph’s Health Care London. 

CCNA was purpose-built to synergize dementia research within the Canadian context. Phase I saw the creation of infrastructure fostering collaboration amongst Canadian researchers, and there are now 20 teams built around important research topics. 

“This kind of effective national collaboration by scientists and clinicians from many disciplines gives the CCNA a cutting edge in research, prevention, treatment and management of all forms of dementia,” explains Dr. Montero-ODasso. “We created a national network of researchers form west to east coast with a high level of expertise to deliver lifestyle interventions to improve cognition and slow down progression to dementia. I feel privileged working with such excellent investigators and leading this important endeavour locally.” 

Preventing dementia through lifestyle changes

The MEC team has several projects in the works, but the majority of the new funding is to complete the SYNERGIC Trial, SYNchronizing Exercises and Remedies on Gait and Cognition. 

This first-in-the-world clinical study is testing a triple intervention aimed at treating Mild Cognitive Impairment (MCI) and delaying the onset of dementia. The SYNERGIC Trial incorporates physical exercises and cognitive training, along with vitamin D supplementation to determine the best treatment for improving mobility and cognition. 

“We are looking at how interventions will work together and targeting cognitive decline at its earliest stage – individuals with MIC,” explains Dr. Montero-Odasso. “Both physical and cognitive exercises have shown promising effects for maintaining cognition, while vitamin D deficiency is associated with cognitive decline.” 

A professor at Western University’s Schulich Medicine & Dentistry, Dr. Montero-Odasso partners with researchers from across the city including Dr. Rob Bartha, imaging scientist at Schulich Medicine & Dentistry and Robarts Research Institute at Western University, and Dr. Kevin Schoemaker who leads the Laboratory for Brain and Heart Health. 

Study participants in the SYNERGIC Trial are asked to complete an individualized and progressive routine of exercises and cognitive training three times a week for six months, with one final assessment at 12 months. The main site for the study is Parkwood Institute with the physical exercises taking place at the Labatt Health Sciences Building on the Western campus.

To date, 138 research patients has been recruited across multiple sites in Canada. 

One participant’s experience 

Image

One day, Peter Saracino saw an advertisement about a research study. They were looking for participants who were a minimum age of 60 and had minor cognitive impairment. He felt he fit the bill and he was interested in this kind of research. 

“I have family members who suffered from forms of dementia and Parkinson’s Disease. I really understand how hard it hits and I liked that this study was about prevention,” explains Peter. 

Going into it, Peter thought he was in pretty good shape. He has two dogs and walks them regularly. “But by going to the gym and doing the exercises and faster-paced walking, I realized that I wasn’t in as good shape as I thought. My diet was under control but I was still taking blood pressure medication. I didn’t have much energy.” 

After 10 weeks in the study, he feels better than he has for over a decade. “I can garden for longer. I took two notches off my belt. I no longer take my blood pressure medication. I actually feel younger.”

He remembered that last year he slipped and fell four times, which was very unusual for him. Part of his cognitive impairment is that he had trouble with balance, and that has improved for him as well. 

Peter feels that “this is exactly the kind of research that the government should be investing in – an ounce of prevention is worth a pound of cure. This kind of research leads to keeping people independent and healthier as they get older. People are happier. They feel like doing more. There is no downside to improving someone’s health through lifestyle changes, and in fact it is cost effective and helps ease the burden on the health care system.” 

Looking forward 

“Our preliminary analysis from SYNERGIC is giving us a strong indication that a multimodal approach, combining physical exercise, cognitive training and supplementation, has a synergistic effect. It seems the whole is greater than the sum of its parts,” says Dr. Montero-Odasso. 

A major goal for the work of the MEC team in London is to translate their research findings into clinical guidelines that can be used at the front line of care. “Practitioners understand the overall importance of exercise and cognitive vitality, but we are missing more specific guidelines on what kind and how much will work for different patients. Basically, what is an effective lifestyle prescription.”

Image

Dr. Montero-Odasso adds that “as our population ages, a comprehensive strategy is vital to ensure the growing number of those living with dementia receive the care and support they deserve. Over half a million Canadians are currently living with dementia. By 2031, this number is expected to nearly double.” More than one third of dementia cases might be preventable. 

CCNA Phase II

In CCNA’s Phase II, researchers are working on analyzing the overall health of every patient in a large clinical cohort study, COMPASS-ND. This information will be used to enhance understanding of how changes in the brain affect dementia severity and ways to reduce and prevent this through lifestyle changes. Lawson is the leading recruitment site for COMPASS-ND and the London team will be instrumental in the larger lifestyle interventions moving forward. 

CCNA is funded by the Government of Canada, Canadian Institutes of Health Research (CIHR) and other funding partners. CIHR is providing $31.6 million, and partners—including provincial agencies and non-profit organizations—are providing an additional $14.4 million for a total investment of $46 million over five years. The research on dementia prevention, diagnosis, treatment and care as part of Phase II of the CCNA will support the national strategy.

Related stories

• Researchers testing triple intervention to combat dementia 
• Lawson and Western researchers suggest walking and talking can be an early predictor of dementia 
• How changes in the brain affect walking while talking in older adults 

More than 100 researchers, staff and trainees attended the third annual Parkwood Institute Research (PIR) Spring Update Half Day on April 27, 2018 to share their innovative research and learn about work from across PIR through interactive workshops and poster presentations.

A program of Lawson Health Research Institute and located at St. Joseph’s Health Care London’s Parkwood Institute, PIR represents three major research programs: cognitive vitality and brain health, mobility and activity, and mental health. The event allowed guests to hear about new studies and recent research developments from across these three themes.

“Parkwood Institute Research covers different research areas but what we want to emphasize with this event is the overlap and collaboration between our programs. Having an inter-disciplinary approach that encourages partnerships ultimately helps us to incorporate new knowledge into patient care at Parkwood Institute,” says Dr. Cheryl Forchuk, Beryl and Richard Ivey Research Chair in Aging, Mental Health, Rehabilitation and Recovery, and Assistant Director, Lawson.

Five interactive workshops were held on a variety of different topics, such as clinical trials, systematic reviews, innovation in health care, practice-based research methods and evaluating SMART technology. The workshops were led by some of Parkwood Institute’s research leaders, including Drs. Cheryl Forchuk, Robert Teasell, Michael Borrie, Dalton Wolfe, and Arlene MacDougall.

Attendees also had the opportunity to visit poster presentations on recent PIR projects.

Image

Ashrafunissa Janmohammad (above), Lawson research coordinator at Parkwood Institute’s Chronic Wound Management Clinic, was one of the poster presenters at the event. She presented on a study led by Lawson associate scientist Dr. David Keast, which assessed whether chitosan gelling fibre dressing could be effective in controlling bleeding after minor wound surgery. Chitosan is derived from chitin, the structural component of the cell walls of fungi and the shells of arthropods such as crabs, lobsters, shrimps and insects.

Image

Juweiriya Ahmed (above), a MSc candidate at Lawson and Western University’s Schulich School of Medicine & Dentistry, was another presenter. Her poster outlined a study investigating the interaction between neuroanatomical and genetic risk factors that may contribute to the development of psychotic symptoms (delusions and hallucinations) in patients with Alzheimer’s disease. Supervised by Lawson scientist Dr. Elizabeth Finger, the study could help inform the development of therapeutic targets and treatment plans.

A research team led by Lawson scientist Dr. Mamadou Diop has been awarded a Lawson Internal Research Fund to investigate whether a previously developed optical technique that can detect arthritis within one week of onset could also be used to provide early assessment of treatment response for rheumatoid arthritis (RA).

RA is a disease that causes chronic inflammation of the joints, which results in pain, reduced quality of life and loss of productivity. There is no cure for RA but a new category of drugs – biologic agents that can reduce pain and slow down or even halt disease progression – has revolutionized treatment.

However, these new drugs are expensive and only work in 30 per cent of patients, which means many RA sufferers are treated with no benefit for up to six months – the time it takes for current monitoring methods to reliably determine whether a treatment is working or not. “This is a direct consequence of the lack of sensitivity of current monitoring methods,” says Dr. Diop, who is also an assistant professor at Western University’s Schulich School of Medicine & Dentistry.

Since their recently developed optical technique has a high sensitivity to arthritis, Dr. Diop and his team believes it could also be used as a safe and convenient method of assessing treatment efficacy in RA patients. Additionally, there are striking similarities between RA and cancer, and it has been shown that optical techniques can predict cancer in as early as one day after therapy starts.

At St. Joseph’s Health Care London, they will test this theory in a rat model of RA and compare the results of the optical technique to histology and CT imaging, other established methods of determining whether a treatment is effective.

“If successful, this project will generate a safe, low-cost technique that can detect treatment response in RA within days of starting treatment. This would reduce the risk of further joint damage experienced by many patients for whom the drugs are ineffective,” says Dr. Diop. “We hope this will enable early redirection of patients with non-responding RA to alternative treatments, such as a combination of multiple drugs and more frequent monitoring.”

Dr. Diop adds, “The Lawson IRF grant will enable us to test the validity of our hypothesis and subsequently generate valuable preliminary results to support grant proposals for larger external funding.”

The IRF is designed to provide Lawson scientists and students the opportunity to obtain start-up funds for new projects with the potential to obtain larger funding, be published in a high-impact journal, or provide a clinical benefit to patients. Funding is provided by the clinical departments of London Health Sciences Centre and St. Joseph’s Health Care London, as well as the hospital foundations (London Health Sciences Foundation and St. Joseph's Health Care Foundation).

The most frequent cause of stroke is Atrial fibrillation (AF), a cardiac arrhythmia consisting of irregular heartbeats. These strokes are the most devastating ones. Recent observations in stroke patients suggest that stroke can also cause AF. This Post-Stroke Atrial Fibrillation (PSAF), in turn, can produce more strokes.

Victoria Thorburn, a Master’s student at Lawson Health Research Institute and Western University’s Schulich School of Medicine & Dentistry in the department of Anatomy and Cell Biology, has been awarded with a Lawson Internal Research Fund (IRF) Studentship to develop the first rodent model of PSAF. The goal of the study is to gain more understanding of the relationship between stroke and PSAF.

The cause of PSAF is currently unknown but it is believed that strokes occurring in the insular cortex, a brain region responsible for monitoring heart rhythm, may trigger PSAF. When this brain region is damaged by stroke, the heart is left without regulation, resulting in chaotic heart rhythms. Previous studies have not been able to confidently diagnose PSAF, since approximately one third of AF cases are silent or asymptomatic.

“Without continuous monitoring of heart rhythm prior to stroke, it is difficult to determine if PSAF is in fact a newly developed arrhythmia occurring after stroke or whether it was actually a silent form of AF that already existed before stroke,” Thorburn says.

Thorburn will experimentally induce stroke in the rat insular cortex to determine whether PSAF or other types of irregular heartbeats occur as a result. The project will be supervised by Dr. Luciano Sposato, Lawson scientist, physician at London Health Sciences Centre and associate professor in the Department of Clinical Neurological Sciences at Schulich, and Dr. Shawn Whitehead, assistant professor at Schulich. They will monitor heartbeat before and after insular stroke then assess potential biological factors or structural changes in the brain or heart that may be associated with PSAF. Animals that developed PSAF will be compared to those without the condition.

Since the proposed cause of PSAF, the involvement of insular cortex damage, differs greatly from the traditional cause of AF, which is often a structural abnormality in the heart, there could also be a difference in treatment. The hope is that the knowledge of PSAF formation gained from the first rodent model will lead to the development of prevention and therapeutic strategies, minimizing the number of stroke patients affected by PSAF and ultimately reducing the recurrence of stroke.

“I wanted to become involved with research that was currently relevant and had the translational potential to improve public health. With the current aging population, the number of individuals directly affected by stroke and AF will continue to rise,” says Thorburn. “Thanks to funding opportunities like Lawson’s IRF, students like myself are able to train alongside accomplished researchers and participate in research that uniquely integrates both basic science and clinical perspectives.”

The IRF is designed to provide Lawson scientists and students the opportunity to obtain start-up funds for new projects with the potential to obtain larger funding, be published in a high-impact journal, or provide a clinical benefit to patients. Funding is provided by the clinical departments of London Health Sciences Centre and St. Joseph’s Health Care London, as well as the hospital foundations (London Health Sciences Foundation and St. Joseph's Health Care Foundation).

Chronic diseases, such as chronic obstructive pulmonary disease (COPD), are complex and require thorough care to help manage the condition. Patients often need support from an integrated team of health care professionals who work in different settings. 

Dr. Shannon Sibbald, associate scientist at Lawson Health Research Institute, is leading a study to better understand integrated health care teams for chronic disease management and factors that help successful implementation. 

Integrated team-based models of care include multiple health care providers working together to support patients with complex needs, such as those with chronic disease. There are many benefits to integrated team-based models of care. Patient outcomes are improved, health care providers feel more supported in their work and services are less likely to be duplicated. 

Dr. Sibbald’s research focuses on chronic obstructive pulmonary disease (COPD), a devastating chronic disease affecting normal lung function in over 1.5 million Canadians. COPD is one example of a chronic disease where patients can benefit from team-based care. COPD is often underdiagnosed, and patients with COPD and other chronic diseases may not be receiving the ideal care for their condition. 

While integrated team-based care is important, there are currently few studies to guide implementation. In this study, Dr. Sibbald’s research team will engage health care providers and patients to gain a rich understanding of successful integrated approaches to chronic disease management, including how team-based models of care are implemented. The team will also work to better understand how patients with chronic diseases view such models, and what their hopes and expectations are for their care. 

“We want to explore innovative and successful approaches to implementing team-based models of care,” explains Dr. Sibbald. “We’re looking to learn how these methods can support practice, improve patient outcomes and spread innovation.”

The team will look at high performing integrated care teams that support current best practices at a family health team in London, Ontario. 

When models are applied to practice, context is an important part to consider. For chronic diseases, context is often broad and elaborate. They hope to gain insight into what works well and what does not in dynamic contexts, and gain a better understanding of implementation facilitators and barriers.

The ultimate goal is to build knowledge that will support implementation and sustainability of high-performing integrated health teams across our health system.

“While motivation and momentum to use integrated teams is high, there is little guidance on how to do this well,” says Dr. Sibbald. “This research will provide insight into what works and what does not, reducing our gap in knowledge.”

Dr. Sibbald received a Lawson Internal Research Fund (IRF) grant to conduct this pilot study. Once complete, Dr. Sibbald’s team hopes to expand the study to look at integrated care models at other sites across the province. 

"The IRF grant enables our team to validate our methods of evaluating the implementation of interprofessional team-based care in complex settings," adds Dr. Sibbald. "By examining the impact team-based care for patients with COPD, we hope to demonstrate the relevance of our findings, to support grant proposals."

The IRF is designed to provide Lawson scientists the opportunity to obtain start-up funds for new projects with the potential to obtain larger funding, be published in a high-impact journal, or provide a clinical benefit to patients. Funding is provided by the clinical departments of London Health Sciences Centre and St. Joseph’s Health Care London, as well as the hospital foundations (London Health Sciences Foundation and St. Joseph’s Health Care Foundation).